Oncology Specialty Focus Biologics has a clear focus on oncology and complex therapies, demonstrated by launches of CABLIVI and TARPEYO and collaborations with Taiho Oncology and Sanofi. This creates cross-sell opportunities for McKesson to provide comprehensive oncology-focused specialty pharmacy services, patient access programs, and related clinical support to new and existing customers.

McKesson Integration Opportunity As Biologics is now part of McKesson, there is a sizable opportunity to bring McKesson's supply chain, healthcare IT, analytics, and financial services to Biologics and its client base, improving operational efficiency and patient access across the network.

High-Touch Patient Services Biologics' TARPEYO Touchpoints and CABLIVI program highlight demand for high-touch patient engagement, affordability assistance, and quick access to therapy—areas where sales teams can upsell expanded patient support services and reimbursement navigation.

Strategic Partnerships The firm has a track record of exclusive specialty pharmacy arrangements (e.g., with Sanofi Genzyme) and pharma collaboration (Taiho Oncology), signaling potential to formalize and scale similar partnerships for other complex therapies and limited distribution products.

Market Footprint Growth Regional operations in North Carolina combined with McKesson's nationwide footprint enable rapid deployment of specialty programs and access services to a broader market, presenting expansion opportunities for new clients and therapies.